| Similar Articles |
|---|
 |
The Motley Fool
June 6, 2006
Brian Lawler |
Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines.   |
The Motley Fool
December 12, 2008
Brian Orelli |
An EXELent Drug Deal Exelixis picks up $195 million in cash in a licensing deal with Bristol-Myers Squibb. |
The Motley Fool
January 3, 2007
Brian Lawler |
Exelixis Busy Selling Its Wares Exelixis inked another development deal with biopharma powerhouse Genentech. Investors, take note. |
The Motley Fool
May 2, 2011
Brian Orelli |
Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror. |
The Motley Fool
November 7, 2007
Brian Lawler |
Following Up on Exelixis Budding development stage pharma Exelixis announces its third-quarter financial results and updates investors on what they can expect for the rest of the year. |
The Motley Fool
May 22, 2009
Brian Orelli |
J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs. |
The Motley Fool
June 5, 2007
Brian Lawler |
Exelixis Presents The pharmaceutical presents data from 2 of its top drug candidates at ASCO. Investors, take note. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
The Motley Fool
December 26, 2007
Brian Lawler |
Exelixis Awaits Bristol-Myers Decision Even if Bristol-Myers Squibb decides to discontinue their partnership, it might not mean the end of the road for Exelixis' cancer treatment. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
The Motley Fool
November 19, 2010
Brian Orelli |
Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all. |
The Motley Fool
September 28, 2006
Brian Lawler |
Exelixis' Growing Share Count The developing biopharmaceutical company announces a share offering. |
The Motley Fool
April 2, 2008
Brian Lawler |
A Slate of Data for Exelixis Exelixis will present analyses of study data at the American Society of Clinical Oncology in May for all of its lead cancer-fighting compounds. Investors, take note. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
July 22, 2008
Brian Lawler |
Anxiously Awaiting Exelixis Pivotal clinical trial results for a top drug are finally within sight. Investors, take note. |
The Motley Fool
September 24, 2007
Brian Lawler |
An Array of Good News Small pharmaceutical firm Array BioPharma signs a big partnership deal with Celgene. Investors, take note. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
June 21, 2007
Brian Orelli |
Dumpster Diving in Pfizer's Trash Investors are probably overreacting to Pfizer's decision, but only time -- and clinical trials -- will tell. |
The Motley Fool
June 11, 2007
Brian Lawler |
Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul. |
The Motley Fool
June 10, 2008
Brian Lawler |
Exelixis Secures Its Future In one of the more complicated financing deals ever made by a development-stage drugmaker, Exelixis brings in enough cash to keep guiding its lead drugs closer to market. |
The Motley Fool
April 29, 2008
Brian Lawler |
Medarex Takes Another Hit Its lead cancer-fighting drug suffers a regulatory delay. |
The Motley Fool
July 23, 2009
Brian Orelli |
The Slowly Wilting Lilly Nothing can save this drug company. |
The Motley Fool
September 10, 2010
Brian D. Pacampara |
A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology. |
The Motley Fool
September 14, 2007
Brian Orelli |
J&J's Expensive RNA Purchase Johnson & Johnson sets up a collaboration with Isis Pharmaceuticals to develop compounds to treat diabetes. Investors take note. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
The Motley Fool
August 31, 2005
Stephen D. Simpson |
Sanofi-Aventis: A Mix of News The company gave investors a lot of information for the second quarter, with not all of it positive. |
The Motley Fool
March 17, 2008
Brian Orelli |
Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis... |
The Motley Fool
June 29, 2007
Brian Lawler |
Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
BusinessWeek
May 28, 2009
Catherine Arnst |
Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs. |
The Motley Fool
June 29, 2007
Brian Orelli |
The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials. |
The Motley Fool
August 31, 2007
Brian Lawler |
4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals. |
The Motley Fool
December 21, 2011
Brian Orelli |
A Biotech Garage Sale Exelixis sells off a preclinical program. |
The Motley Fool
May 28, 2010
Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
The Motley Fool
December 27, 2011
Brian Orelli |
Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA. |
The Motley Fool
September 8, 2011
Brian Orelli |
Delayed Data Coming Soon? EXELent! Exelixis should have data on cabozantinib early in the fourth quarter. |
The Motley Fool
October 11, 2010
Brian Orelli |
A Dendreon Killer? Not Yet. Johnson & Johnson's abiraterone looks good, but won't knock off the newcomer. |
The Motley Fool
July 24, 2009
Brian Orelli |
Bristol-Myers: Eat or Be Eaten Bristol-Myers Squibb, the oft-rumored acquisition target of partner sanofi-aventis, is doing a little acquiring of its own, which might settle down the rumor mill. |
The Motley Fool
June 30, 2009
Brian Orelli |
One-Drug Wonders Deserve a Spot in Your Portfolio Looking a little more appetizing these days. |
The Motley Fool
May 18, 2011
Brian Orelli |
5 Biotech ASCO Abstracts to Watch The biotech investors' Christmas in May is once again upon us, where investors and researchers alike will be able to find the synopsis of what will be presented at the American Society of Clinical Oncology annual meeting next month. |
The Motley Fool
November 18, 2004
Charly Travers |
A Glimpse of Bristol-Myers' Portfolio Late-stage drugs are crucial for a company beset with patent losses. |
The Motley Fool
June 13, 2008
Brian Lawler |
Glaxo Gears Up a Blockbuster One of the pharmaceutical's top new compounds scores final EU approval. |
The Motley Fool
December 17, 2007
Brian Lawler |
Glaxo, Exelixis Trade Gifts Glaxo announces that it will take over development of a lead Exelixis drug. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
March 31, 2008
Brian Lawler |
SGX Down for the Count? The pharmaceutical's lead drug fares poorly in clinical testing. |
The Motley Fool
November 30, 2007
Brian Orelli |
Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way. |
The Motley Fool
June 21, 2010
Luke Timmerman |
Bristol-Myers Dumps Exelixis Drug There is an exit payment for Exelixis. |
